Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). Because The Cancer Genome Atlas defined an EC molecular classification with strong prognostic value, we investigated prognosis and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants. METHODS Paraffin-embedded tissues of 423 consenting patients were collected. Immunohistochemistry for p53 and mismatch repair (MMR) proteins, and DNA sequencing for POLE exonuclease…

• CR
  Cancer Research Institute
• NC
  National Cancer Research Institute
• NI
  National Institute for Health and Care Research

  Awards: BRC-1215-20007, IS-BRC-1215, IS-BRC-1215-20007
• KK
  KWF Kankerbestrijding

  Awards: PORTEC-3, IS-BRC-1215-20007, 10418
• IG
  Institut Gustave-Roussy

  Award: IS-BRC-1215-20007
• MB
  Manchester Biomedical Research Centre

  Awards: IS-BRC-1215-20007, BRC-1215-20007, 20007, IS-BRC-1215